CRBU Caribou Biosciences, Inc. Common Stock
XNAS
7.80
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CRBU
$7.80
—
What changed
Recent filings, trades and movesKey stats
$7.80
- 52-Week Range
- $0.40 – $2.49
- YTD
- +390.57%
- Straddle Price
- $14.55
- P/C Vol Ratio
- 0.25
- Market Cap
- $0.0B
- Open
- $0.44
- Day Range
- $0.41 – $0.46
- Volume
- 2,550,659
- Prev Close
- $0.45
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.66 |
| Cost of Equity (CAPM) | 14.01% (VRP-adj) |
| WACC | 14.15% |
| Volatility Risk Premium | +351.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -105.6% |
| Book / Price | 216.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -954.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $0.95 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.47 |
| Bollinger Width / SMA20 | 32.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, KYMR, MRNA, NBIX, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$2.56
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 30.1× · 6 peers |
| Peer EV/EBITDA | n/a | 0% | median 16.9× · 7 peers |
| Peer P/B | $11.37 | 16% | median 11.7× · 10 peers |
| Peer P/S | $0.75 | 16% | median 7.6× · 10 peers |
| Market Anchor (SMA50) | $0.95 | 69% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 97
- List Date
- 2021-07-23
- CIK
- 0001619856
- Last Earnings
- Nov 5 after close · +9.8% vs ±624.5% expected
- Headquarters
- Berkeley, CA
- Homepage
- https://www.cariboubio.com
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United State…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -29.96% | 9.08% | 10.05% | -14.88% | -11.32% | -7.41% |
| Feb | -- | -10.17% | -18.03% | 18.24% | -14.60% | 30.14% | 1.12% |
| Mar | -- | -1.82% | -11.94% | -34.02% | -14.66% | 3.26% | -11.84% |
| Apr | -- | -19.74% | -21.39% | -28.12% | 1.17% | -5.53% | -14.72% |
| May | -- | 5.04% | 0.00% | -21.95% | 32.20% | 26.20% | 8.30% |
| Jun | -- | -34.81% | -7.21% | -23.54% | 29.24% | -27.57% | -12.78% |
| Jul | -0.74% | 52.06% | 76.23% | 45.91% | 62.40% | -17.05% | 36.47% |
| Aug | 55.34% | 23.07% | -19.43% | -3.57% | -4.10% | 2.67% | 9.00% |
| Sep | -11.53% | 0.29% | -18.71% | -1.01% | 23.94% | -18.06% | -4.18% |
| Oct | -0.90% | -8.11% | -19.87% | 7.10% | 7.08% | -65.31% | -13.34% |
| Nov | -16.22% | -3.82% | 63.97% | -0.90% | -20.16% | -5.36%* | 2.92% |
| Dec | -10.87% | -31.44% | 0.70% | -32.91% | -10.17% | -- | -16.94% |
| Total | 0.95% | -61.39% | -12.29% | -63.47% | 58.96% | -76.42% | -25.61% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.47
SMA 50: $0.93
SMA 200: $1.60
Current: $0.41
EMA 12: $0.46
EMA 26: $0.60
MACD: -0.1358 | Signal: 0.0267
BEARISH
ADX (14): 58.53
STRONG TREND
+DI: 11.75
−DI: 35.16
Momentum Oscillators
RSI (14): 28.92
OVERSOLD
Stoch %K: 13.52
Stoch %D: 16.61
Williams %R: -92.04
Volume & Volatility
BB Upper: $0.55
BB Lower: $0.39
NEUTRAL
OBV: -26,278,142
Vol SMA 20: 2,555,014
Vol ROC: 31.76%
ATR: $0.06
True Range: $0.05
HV 20: 96.1%
HV 30: 203.8%
HV 60: 149.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All CRBU news →
Earnings History
16 of 18 under expected move
Avg Expected Move
105.98%
Avg Actual Move
9.14%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-03-21 | After-Close | 17.27% | 9.51% | 0.55x | Within |
| 2022-05-09 | After-Close | 14.99% | 9.30% | 0.62x | Within |
| 2022-08-09 | After-Close | 18.43% | 14.25% | 0.77x | Within |
| 2023-05-09 | After-Close | 27.50% | 6.82% | 0.25x | Within |
| 2023-07-13 | After-Close | 14.74% | 22.60% | 1.53x | Exceeded |
| 2023-11-07 | After-Close | 11.11% | 5.03% | 0.45x | Within |
| 2024-03-11 | After-Close | 10.80% | 30.47% | 2.82x | Exceeded |
| 2024-05-07 | After-Close | 19.03% | 6.17% | 0.32x | Within |
| 2024-08-06 | After-Close | 40.92% | 2.81% | 0.07x | Within |
| 2024-11-06 | Pre-Market | 23.44% | 7.42% | 0.32x | Within |
| 2025-03-10 | Pre-Market | 247.84% | 4.74% | 0.02x | Within |
| 2025-05-08 | Pre-Market | 657.89% | 3.95% | 0.01x | Within |
| 2025-08-12 | After-Close | 47.49% | 8.94% | 0.19x | Within |
| 2025-11-12 | After-Close | 29.87% | 12.17% | 0.41x | Within |
| 2026-03-05 | After-Close | 54.09% | 6.43% | 0.12x | Within |
| 2026-05-07 | After-Close | 26.60% | 3.19% | 0.12x | Within |
| 2026-08-11 | Pre-Market | 21.08% | 1.81% | 0.09x | Within |
| 2026-11-05 | After-Close | 624.55% | 8.83% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CRBU Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $14.55
7-DTE Move: $14.90
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 717
Put Volume: 180
P/C Volume: 0.251
BULLISH
Call OI: 7,286
Put OI: 431
P/C OI: 0.059
Total OI: 7,717
ATM Options Pricing
ATM Call: $7.50
ATM Put: $7.05
Call %: 96.2%
Put %: 90.4%
Chain Summary
Chain Volume: 897
Chain OI: 7,717
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 29th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
29%
vs own history
GEX tilt
+0.32
OI-weighted, today
Vanna tilt
+0.42
δ-sensitivity to IV
Charm tilt
-0.40
δ-decay vs time
Vanna tilt +0.42: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.40: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$14.55Nov 9
Beta Analysis
Risk Metrics
Beta: 1.8033
Alpha: -143.52%
Correlation: 0.2941
R-Squared: 8.6%
Stock Volatility: 84.5%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CRBU
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $4.9M | #1479 of 3138 | +7.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $90K | #3628 of 3716 | -95.2% | 13F | |
| Citadel Hedge fund Ken Griffin | $71K | #5899 of 6285 | -74.6% | 13F | |
| Point72 Hedge fund Steve Cohen | $28K | #1903 of 1945 | -91.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CRBU Institutional Ownership (13F)
Filings for 2026-06-30 · 52 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 96,174,088 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$515.25K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $217.01K | 42.12% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $120.03K | 23.30% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $76.83K | 14.91% | 2026-09-30 |
| 4 | Jane Street Group, LLC Custodian | $66.70K | 12.95% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $34.67K | 6.73% | 2026-06-30 |
4 filers$174.12K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $80.43K | 46.19% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $60.02K | 34.47% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $20.59K | 11.83% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $13.08K | 7.51% | 2026-09-30 |
CRBU Insider Trading (Form 4)
Latest: 2026-02-27Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-27 | Timothy P Kelly | Chief Technology Officer | Sell (S) | −6,228 | $1.93 | -$12.0K | EDGAR |
| 2026-02-24 | Ruhi Ahmad Khan | Chief Business Officer | Mixed Sell −6,938 · Grant +45,000 |
+38,062 | $1.96 | -$13.6K | EDGAR |
| 2026-02-24 | Tina M. Albertson | Chief Medical Officer | Mixed Sell −1,066 · Grant +55,000 |
+53,934 | $1.96 | -$2.1K | EDGAR |
| 2026-02-24 | Barbara G McClung | Chief Legal Officer | Mixed Grant +45,000 · Sell −6,938 |
+38,062 | $1.96 | -$13.6K | EDGAR |
| 2026-02-24 | Timothy P Kelly | Chief Technology Officer | Mixed Grant +45,000 · Sell −3,147 |
+41,853 | $1.96 | -$6.2K | EDGAR |
| 2026-02-20 | Dara Richardson-Heron | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | Natalie Sacks | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | David Lee Johnson | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | Nancy Whiting | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | Ran Zheng | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | Andrew Guggenhime | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | Scott Braunstein | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-20 | Rachel E. Haurwitz | President and CEO | Award (A) | +151,700 | — | EDGAR | |
| 2026-02-20 | Sriram Ryali | Chief Financial Officer | Award (A) | +55,000 | — | EDGAR | |
| 2025-03-17 | Rachel E. Haurwitz | President and CEO | Buy (P) | +20,000 | $1.02 | $20.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CRBU Insider Holdings
8 insiders · @ $0.41
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rachel E. Haurwitz | President and CEO | 3,816,545 | $1.58M | $20.4K | 11 | 2026-02-20 |
| 2 | Barbara G McClung | Chief Legal Officer | 481,564 | $199.8K | $22.9K | 8 | 2026-02-24 |
| 3 | Steven Kanner | Chief Scientific Officer | 431,556 | $179.1K | -$269.3K | 10 | 2025-02-21 |
| 4 | Ryan Fischesser | VP of Finance and Controller | 118,854 | $49.3K | -$70.7K | 8 | 2024-11-22 |
| 5 | Ruhi Ahmad Khan | Chief Business Officer | 111,936 | $46.5K | -$18.4K | 6 | 2026-02-24 |
| 6 | Timothy P Kelly | Chief Technology Officer | 73,125 | $30.3K | -$18.2K | 4 | 2026-02-27 |
| 7 | Sriram Ryali | Chief Financial Officer | 72,360 | $30.0K | $24.7K | 3 | 2026-02-20 |
| 8 | Tina M. Albertson | Chief Medical Officer | 69,589 | $28.9K | -$2.1K | 3 | 2026-02-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CRBU Board & Officers
As of SEC filings through Feb 27, 2026Directors 8
- Andrew Guggenhime · since Jul 22, 2021
- Natalie Sacks · since Jul 22, 2021
- Rachel E. Haurwitz · since Jul 22, 2021
- Scott Braunstein · since Jul 22, 2021
- Nancy Whiting · since Aug 24, 2021
- Ran Zheng · since Sep 24, 2021
- Dara Richardson-Heron · since Nov 4, 2021
- David Lee Johnson · since May 11, 2022
Officers 6
- Rachel E. Haurwitz · President and CEO · since Jul 22, 2021
- Sriram Ryali · Chief Financial Officer · since Jan 2, 2025
- Barbara G McClung · Chief Legal Officer · since Jul 22, 2021
- Ruhi Ahmad Khan · Chief Business Officer · since Nov 8, 2021
- Timothy P Kelly · Chief Technology Officer · since Jan 1, 2024
- Tina M. Albertson · Chief Medical Officer · since Aug 12, 2024
Changes in the last 10 years (20)
| Jan 2, 2025 | Sriram Ryali became Chief Financial Officer |
| Aug 12, 2024 | Tina M. Albertson became Chief Medical Officer |
| Jan 1, 2024 | Timothy P Kelly became Chief Technology Officer |
| Dec 11, 2023 | The company announced the departure of Syed Ali-aamir Rizvi as Chief Medical Officer in an SEC filing |
| May 11, 2022 | David Lee Johnson became a director |
| Jan 18, 2022 | Syed Ali-aamir Rizvi became Chief Medical Officer |
| Nov 8, 2021 | Ruhi Ahmad Khan became Chief Business Officer |
| Nov 4, 2021 | Dara Richardson-Heron became a director |
| Sep 24, 2021 | Ran Zheng became a director |
| Aug 24, 2021 | Nancy Whiting became a director |
| Jul 22, 2021 | Steven Kanner became Chief Scientific Officer |
| Jul 22, 2021 | Scott Braunstein became a director |
| Jul 22, 2021 | Ryan Fischesser became VP of Finance and Controller |
| Jul 22, 2021 | Rachel E. Haurwitz became a director |
| Jul 22, 2021 | Rachel E. Haurwitz became President and CEO |
| Jul 22, 2021 | Natalie Sacks became a director |
| Jul 22, 2021 | Jeffrey Stephen Long-McGie became a director |
| Jul 22, 2021 | Jason O'Byrne became Chief Financial Officer |
| Jul 22, 2021 | Barbara G McClung became Chief Legal Officer |
| Jul 22, 2021 | Andrew Guggenhime became a director |
Not reported recently (4)
- Steven Kanner · Last reported as Chief Scientific Officer in an SEC filing dated Feb 21, 2025
- Ryan Fischesser · Last reported as VP of Finance and Controller in an SEC filing dated Nov 22, 2024
- Jason O'Byrne · Last reported as Chief Financial Officer in an SEC filing dated Feb 22, 2024
- Jeffrey Stephen Long-McGie · Last reported as a director in an SEC filing dated Jul 22, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CRBU Proposed Insider Sales (Form 144)
Latest: 2026-02-25
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-02-25 | TIMOTHY KELLY | Officer | 6,228 | $12.1K | 2026-02-25 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-25 | RUHI AHMAD KHAN | Officer | 6,938 | $13.6K | 2026-02-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-25 | BARBARA G MCCLUNG | Officer | 6,938 | $13.6K | 2026-02-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
26 ETFs hold CRBU
25 shown · $9.78M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $3.8M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.7M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $1.0M | $76.6B | 2026-11-06 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $674,858 | — | 2026-09-30 |
| 5 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $648,893 | — | 2026-08-31 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $396,244 | $13.9B | 2026-11-06 |
| 7 | NXTE AXS Green Alpha ETF | Nport | 0.62% | $355,258 | — | 2026-06-30 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.00% | $302,129 | $11.1B | 2026-11-06 |
| 9 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.00% | $144,637 | $6.6B | 2026-11-05 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $123,800 | $1.2B | 2026-11-06 |
| 11 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $123,018 | — | 2026-08-31 |
| 12 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $120,171 | — | 2026-07-31 |
| 13 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $107,174 | — | 2026-09-30 |
| 14 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.03% | $66,584 | — | 2026-11-05 |
| 15 | GNOM Global X Genomics & Biotechnology ETF | Global X | 0.04% | $44,335 | — | 2026-11-06 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $43,458 | — | 2026-11-05 |
| 17 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $19,919 | — | 2026-11-06 |
| 18 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $11,449 | — | 2026-09-30 |
| 19 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.00% | $3,163 | — | 2026-11-05 |
| 20 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $2,330 | — | 2026-11-06 |
| 21 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.00% | $2,019 | — | 2026-11-06 |
| 22 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $1,806 | — | 2026-11-06 |
| 23 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $1,230 | — | 2026-11-06 |
| 24 | GNMX Corgi Genomics & Precision Medicine ETF | Corgi | 0.07% | $873 | $1.3M | 2026-11-06 |
| 25 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $51 | — | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.08
TTM Revenue
$10.04M
TTM Net Income
$-103.56M
TTM Op. Cash Flow
$-95.78M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $1.50M | $-24.28M | $-0.24 | $-22.79M |
| Q1 '26 | 2026-03-31 | $2.40M | $-25.09M | $-0.26 | $-26.98M |
| Q4 '25 | 2025-12-31 | $3.94M | $-26.64M | $-0.28 | $-20.82M |
| Q3 '25 | 2025-09-30 | $2.20M | $-27.55M | $-0.30 | $-25.18M |
| Q2 '25 | 2025-06-30 | $2.67M | $-54.10M | $-0.58 | $-28.26M |
| Q1 '25 | 2025-03-31 | $2.35M | $-39.99M | $-0.43 | $-36.73M |
| Q4 '24 | 2024-12-31 | $2.08M | $-35.27M | $-0.39 | $-35.47M |
| Q3 '24 | 2024-09-30 | $2.02M | $-34.68M | $-0.38 | $-32.66M |
| Q2 '24 | 2024-06-30 | $3.46M | $-37.70M | $-0.42 | $-32.87M |
| Q1 '24 | 2024-03-31 | $2.43M | $-41.23M | $-0.46 | $-37.20M |
| Q4 '23 | 2023-12-31 | $3.56M | $-34.51M | $-0.40 | $-21.38M |
| Q3 '23 | 2023-09-30 | $23.66M | $-10.00M | $-0.12 | $-28.79M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.41
P/S
3.99
EV/EBITDA
—
EV/Sales
1.38
ROE
-105.6%
ROA
-72.5%
Div Yield
0.00%
FCF Yield
-239.23%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$40.04M
as of 2026-11-09
CRBU vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.8% | 60 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +795.8% | 51 |
| BNTX BioNTech SE American Depositary Share | $21.7B | — | — | −8.5% | 38 |
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +57.5% | 25 |
| CRSP CRISPR Therapeutics AG | $4.9B | — | −34.3% | −5.8% | 38 |
| RXRX Recursion Pharmaceuticals, Inc. Class A | $2.2B | — | +56.2% | −9.0% | 23 |
| PRME Prime Medicine, Inc. Common Stock | $843M | — | −17.9% | +24.8% | 69 |
| CRBU Caribou Biosciences, Inc. Common Stock | $48M | — | +10.0% | −73.9% | 46 |
| HXSCF SK HYNIX INC | — | — | — | — | — |
| Peer median | $20.4B | 35.4 | −3.7% | +21.8% | 38 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
12.55M
SI % of Float
13.47%
Days to Cover
1.54
Short Vol Ratio
65.9%
Free Float
93.21M
Float %
86.9%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22